←
Capricor Therapeutics841 posts
Capricor Therapeutics avatar

Capricor Therapeutics

@Capricor

Capricor (NASDAQ: $CAPR) is a biotech company focused on the development of cell & exosome-based therapeutics for treatment and prevention of serious diseases.

◷ Joined July 2014▧ 623 Photos and videos
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Nov 9

This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible. Read the press release: bit.ly/4BMIYM5 #AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR

Post attachment
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Oct 7

Today at 1:00 p.m. ET, Capricor and @PPMD are hosting a webinar on the latest HOPE-3 open-label extension 2-year results, presented last week at the World Muscle Society Congress in Japan. We will walk through the data in more detail and discuss what these results may mean for the Duchenne muscular dystrophy community. Register here: bit.ly/3Ubm3c8 $CAPR #Deramiocel #PPMD #Duchenne #DMD

Post attachment
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Oct 5

Capricor today announced new 24-month data from the HOPE-3 open-label extension, presented last week in a late-breaking poster at the 2026 World Muscle Society Congress in Hiroshima, Japan. Patients who began Deramiocel after a year on placebo experienced a 76% reduction in their rate of upper limb decline compared with their own prior year. At 24 months, both treatment groups had declined less than natural history predicts. Read the full press release: bit.ly/4ANTtOD #Duchenne #DMD #WMS2026 #Deramiocel $CAPR

Post attachment
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Sep 17

Capricor is headed to the 2026 World Muscle Society Congress in Hiroshima, Japan, September 29 – October 3. We’re looking forward to sharing new HOPE-3 open-label extension data for Deramiocel in Duchenne muscular dystrophy, including skeletal muscle and cardiac outcomes through 24 months. Dr. Craig McDonald of UC Davis will present the findings in a late-breaking poster and an oral presentation, alongside additional research from our StealthX™ platform exploring muscle-targeting extracellular vesicle technologies. We’re proud to continue advancing the science and working toward better options for boys and families living with Duchenne. 💙 Read more: bit.ly/3TFiBWZ $CAPR #Deramiocel #Duchenne #DMD #exosomes #WMS2026 #WorldMuscleSociety

Post attachment
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Sep 7

Today, we join the global community in recognizing World Duchenne Awareness Day. This year’s theme, “Access Changes Lives,” reminds us that meaningful progress goes beyond just scientific breakthroughs. It means ensuring that individuals living with Duchenne and Becker muscular dystrophy have access to the care, support, and opportunities they need. At Capricor, we remain committed to continuing to push forward with Deramiocel and our mission to help make a difference in the lives of those living with DMD. Together, we can raise awareness, inspire action, and work toward a brighter future for the Duchenne community. 💚 $CAPR #WDAD2026 #DuchenneAwareness #DMD #AccessChangesLives #Deramiocel

Post attachment
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Jul 29

“Behind every dataset is a patient waiting for more time, more function and more independence.” – Dr. Linda Marbán, Capricor CEO Today's FDA Advisory Committee meeting is underway. Watch live: youtube.com/live/SUNn6YcBhnw

Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Jul 29

We're pleased to share that @TheLancet has published results from Capricor's Phase 3 HOPE-3 trial evaluating Deramiocel in #Duchenne muscular dystrophy. The independent peer-reviewed publication validates the trial's design, statistical methodology and findings. HOPE-3 met its primary endpoint, with Deramiocel slowing upper limb function decline by 54 percent versus placebo (PUL 2.0, p=0.03) and demonstrating a clinically meaningful cardiac benefit. Read more here: thelancet.com/journals/lance… We are grateful to the patients, families, investigators and study teams who made this research possible.

Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Jul 28

Capricor's FDA Advisory Committee meeting will be livestreamed tomorrow, July 29, from 9:30 a.m. to 5 p.m. EST. We invite shareholders, analysts, partners and the broader DMD community to tune in here: lnkd.in/gdv7tqhM Thank you for your continued support.

Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Jun 10

Today, our CEO, Linda Marbán, presented at the Oppenheimer CNS & NeuroMuscular Summit in Miami, Florida, alongside leaders from Sarepta and Dyne during the “Advancing Duchenne: Perspectives From Industry Leaders” panel. Proud to be part of the important conversations shaping the future of Duchenne muscular dystrophy treatment and innovation.

Post attachmentPost attachment
Capricor Therapeutics avatar
Capricor Therapeutics@Capricor·Jun 8

Capricor will be participating in two investor conferences this week in Miami — the Goldman Sachs 47th Annual Global Healthcare Conference (fireside chat, June 10 at 10:00 a.m. ET) and the Oppenheimer CNS and Neuro-Muscular Summit. To view the Goldman Sachs webcast, click here. bit.ly/3POYzHT $CAPR #DMD #Deramiocel

Post attachment